These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 25240761)

  • 1. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
    Armstrong AJ; Kaboteh R; Carducci MA; Damber JE; Stadler WM; Hansen M; Edenbrandt L; Forsberg G; Nordle Ö; Pili R; Morris MJ
    Urol Oncol; 2014 Nov; 32(8):1308-16. PubMed ID: 25240761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.
    Armstrong AJ; Häggman M; Stadler WM; Gingrich JR; Assikis V; Polikoff J; Damber JE; Belkoff L; Nordle Ö; Forsberg G; Carducci MA; Pili R
    Clin Cancer Res; 2013 Dec; 19(24):6891-901. PubMed ID: 24255071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Armstrong AJ; Anand A; Edenbrandt L; Bondesson E; Bjartell A; Widmark A; Sternberg CN; Pili R; Tuvesson H; Nordle Ö; Carducci MA; Morris MJ
    JAMA Oncol; 2018 Jul; 4(7):944-951. PubMed ID: 29799999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer.
    Uemura K; Miyoshi Y; Kawahara T; Yoneyama S; Hattori Y; Teranishi J; Kondo K; Moriyama M; Takebayashi S; Yokomizo Y; Yao M; Uemura H; Noguchi K
    BMC Cancer; 2016 Feb; 16():109. PubMed ID: 26883015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials.
    Mota JM; Armstrong AJ; Larson SM; Fox JJ; Morris MJ
    Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):522-530. PubMed ID: 31036925
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Fosbøl MØ; Petersen PM; Kjaer A; Mortensen J
    J Nucl Med; 2018 Apr; 59(4):596-602. PubMed ID: 28864632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flare phenomenon visualized by
    Zhang X; Nakajima K; Mizokami A; Horikoshi H; Nishimoto K; Hashine K; Matsuyama H; Takahashi S; Wakabayashi H; Kinuya S
    Ann Nucl Med; 2024 Jun; 38(6):428-440. PubMed ID: 38478154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
    Sternberg C; Armstrong A; Pili R; Ng S; Huddart R; Agarwal N; Khvorostenko D; Lyulko O; Brize A; Vogelzang N; Delva R; Harza M; Thanos A; James N; Werbrouck P; Bögemann M; Hutson T; Milecki P; Chowdhury S; Gallardo E; Schwartsmann G; Pouget JC; Baton F; Nederman T; Tuvesson H; Carducci M
    J Clin Oncol; 2016 Aug; 34(22):2636-43. PubMed ID: 27298414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
    Pili R; Häggman M; Stadler WM; Gingrich JR; Assikis VJ; Björk A; Nordle O; Forsberg G; Carducci MA; Armstrong AJ
    J Clin Oncol; 2011 Oct; 29(30):4022-8. PubMed ID: 21931019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study.
    Zacho HD; Gade M; Mortensen JC; Bertelsen H; Boldsen SK; Barsi T; Petersen LJ
    Urology; 2017 Oct; 108():135-141. PubMed ID: 28760556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer.
    Perez-Lopez R; Lorente D; Blackledge MD; Collins DJ; Mateo J; Bianchini D; Omlin A; Zivi A; Leach MO; de Bono JS; Koh DM; Tunariu N
    Radiology; 2016 Jul; 280(1):151-60. PubMed ID: 26807894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing Radiographic Response to
    Anand A; Trägårdh E; Edenbrandt L; Beckman L; Svensson JH; Thellenberg C; Widmark A; Kindblom J; Ullén A; Bjartell A
    J Nucl Med; 2020 May; 61(5):671-675. PubMed ID: 31586004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.
    Poulsen MH; Rasmussen J; Edenbrandt L; Høilund-Carlsen PF; Gerke O; Johansen A; Lund L
    BJU Int; 2016 May; 117(5):748-53. PubMed ID: 25906907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of the bone scan index in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
    Song H; Jin S; Xiang P; Hu S; Jin J
    BMC Cancer; 2020 Mar; 20(1):238. PubMed ID: 32197590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment.
    Frantellizzi V; Pani A; Ippoliti MD; Farcomeni A; Aloise I; Colosi M; Polito C; Pani R; Vincentis G
    Radiol Oncol; 2019 Dec; 54(1):40-47. PubMed ID: 31855572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
    Dennis ER; Jia X; Mezheritskiy IS; Stephenson RD; Schoder H; Fox JJ; Heller G; Scher HI; Larson SM; Morris MJ
    J Clin Oncol; 2012 Feb; 30(5):519-24. PubMed ID: 22231045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel.
    Uemura K; Miyoshi Y; Kawahara T; Ryosuke J; Yamashita D; Yoneyama S; Yokomizo Y; Kobayashi K; Kishida T; Yao M; Uemura H
    BMC Cancer; 2018 May; 18(1):501. PubMed ID: 29716525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide.
    Anand A; Morris MJ; Larson SM; Minarik D; Josefsson A; Helgstrand JT; Oturai PS; Edenbrandt L; Røder MA; Bjartell A
    EJNMMI Res; 2016 Dec; 6(1):23. PubMed ID: 26960325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice.
    Reza M; Ohlsson M; Kaboteh R; Anand A; Franck-Lissbrant I; Damber JE; Widmark A; Thellenberg-Karlsson C; Budäus L; Steuber T; Eichenauer T; Wollmer P; Edenbrandt L; Trägårdh E; Bjartell A
    Eur Urol Focus; 2016 Dec; 2(5):540-546. PubMed ID: 28723520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment.
    Fukai S; Daisaki H; Umeda T; Shimada N; Terauchi T; Koizumi M
    Ann Nucl Med; 2024 Jun; 38(6):450-459. PubMed ID: 38517659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.